Literature DB >> 31422359

Outcomes of patients with severe tricuspid regurgitation and congestive heart failure.

Amer N Kadri1, Vivek Menon1, Yasser M Sammour2, Rama D Gajulapalli1, Chandramohan Meenakshisundaram1, Leen Nusairat1, Divyanshu Mohananey1, Adrian V Hernandez3,4, Jose Navia5, Amar Krishnaswamy2, Brian Griffin2, Leonardo Rodriguez2, Serge C Harb2, Samir Kapadia6.   

Abstract

OBJECTIVES: A substantial number of patients with severe tricuspid regurgitation (TR) and congestive heart failure (CHF) are medically managed without undergoing corrective surgery. We sought to assess the characteristics and outcomes of CHF patients who underwent tricuspid valve surgery (TVS), compared with those who did not.
METHODS: Retrospective observational study involving 2556 consecutive patients with severe TR from the Cleveland Clinic Echocardiographic Database. Cardiac transplant patients or those without CHF were excluded. Survival difference between patients who were medically managed versus those who underwent TVS was compared using Kaplan-Meier survival curves. Multivariate analysis was performed to identify variables associated with poor outcomes.
RESULTS: Among a total of 534 patients with severe TR and CHF, only 55 (10.3%) patients underwent TVS. Among the non-surgical patients (n=479), 30% (n=143) had an identifiable indication for TVS. At 38 months, patients who underwent TVS had better survival than those who were medically managed (62% vs 35%; p<0.001). On multivariate analysis, advancing age (HR: 1.23; 95% CI 1.12 to 1.35 per 10-year increase in age), moderate (HR: 1.39; 95% CI 1.01 to 1.90) and severe (HR: 2; 95% CI 1.40 to 2.80) right ventricular dysfunction were associated with higher mortality. TVS was associated with lower mortality (HR: 0.44; 95% CI 0.27 to 0.71).
CONCLUSION: Although corrective TVS is associated with better outcomes in patients with severe TR and CHF, a substantial number of them continue to be medically managed. However, since the reasons for patients not being referred to surgery could not be ascertained, further randomised studies are needed to validate our findings before clinicians can consider surgical referral for these patients. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  heart failure; tricuspid regurgitation; valvular heart disease

Mesh:

Year:  2019        PMID: 31422359     DOI: 10.1136/heartjnl-2019-315004

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

Review 1.  [ESC/EACTS guidelines 2021 on the management of valvular heart diseases : What are the most important innovations?]

Authors:  F S Nettersheim; S Baldus
Journal:  Herz       Date:  2021-10-05       Impact factor: 1.443

2.  Live Three-Dimensional Multiplanar Reconstruction Imaging Guidance for Concomitant Mitral and Tricuspid Valve Repairs Using the MitraClip.

Authors:  Tom Kai Ming Wang; Serge C Harb; Rhonda L Miyasaka; John Wagener; Amar Krishnaswamy; Grant K Reed; Samir R Kapadia
Journal:  CASE (Phila)       Date:  2020-02-11

3.  Surgical management of tricuspid regurgitation: a new algorithm to minimise recurrent tricuspid regurgitation.

Authors:  Diego Rodriguez Torres; Lucía Torres Quintero; Diego Segura Rodríguez; Jose Manuel Garrido Jimenez; Maria Esteban Molina; Francisco Gomera Martínez; Eduardo Moreno Escobar; Rocio Garcia Orta
Journal:  Open Heart       Date:  2022-07

4.  Tricuspid regurgitation: remembering 'the forgotten valve'.

Authors:  R J de Winter
Journal:  Neth Heart J       Date:  2022-08-03       Impact factor: 2.854

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.